HSK46256 / Haisco - LARVOL DELTA

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=275 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.

New P1 trial • Oncology • Solid Tumor • HRD

HSK46256, a highly selective and brain penetrable PARP1 inhibitor for the treatment of HRD cancers (AACR 2025) - "The CNS penetration of HSK46256 in rodent showed an unbound partition coefficient (Kpuu) of 0.32, indicating good CNS penetration compared to Kpuu of 0.25 of AZD9574. HSK46256 may offer a more efficacious and less toxic cancer treatment compared with currently approved PARPi especially when used in combination with other anti-cancer agents. Furthermore, owing to its CNS penetration capability HSK46256 may provide a new treatment option for patients with CNS malignancies or patients with brain metastases, where HRR suppression or HRD exists or for cancers with high rates of brain metastases."

Late-breaking abstract • Brain Cancer • CNS Tumor • Oncology • Solid Tumor • BRCA • HRD • PARP2